Article

Non-specificity fingerprints for clinical stage antibodies in solution

2023-02-14

Abstract excerpt

Monoclonal antibodies (mAbs) have successfully been developed for the treatment of a wide range of diseases. The clinical success of mAbs, does not solely rely on optimal potency and safety, but also require good biophysical properties to ensure high developability potential. In particular, non-specific interactions are a key developability measure to monitor during discovery. Despite an increased focus on the det...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f974222e-c2d3-5ae0-bdb1-f5b946a1f44b
DOI: 10.1101/2023.02.13.528263

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Non-specificity fingerprints for clinical stage antibodies in solutionDOI 10.1101/2023.02.13.528263Read

Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning.Semantic proximity Read

Microfluidics-enabled fluorescence-activated cell sorting of single pathogen-specific antibody secreting cells for the rapid discovery of monoclonal antibodiesSemantic proximity Read

Monoclonal antibodies: From magic bullet to precision weaponSemantic proximity Read

Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approachesSemantic proximity Read

Enhancing viscosity control in antibody formulations: A framework for the biophysical screening of mutations targeting solvent-accessible hydrophobic and electrostatic patchesSemantic proximity Read

Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD-20 therapySemantic proximity Read

The Influence of Variable-Heavy (V <sub>H</sub> ) Chain Families on IgG <sub>2</sub> , <sub>3</sub> , <sub>4</sub> on FcγRs and Antibody Superantigens Protein G and L Binding using Biolayer InterferometrySemantic proximity Read

Probing Interactions of Therapeutic Antibodies with Serum via Second Virial Coefficient MeasurementsSemantic proximity Read

Immunogenicity of Therapeutic Antibodies: Mechanisms, Prediction, and Mitigation Strategies in the Era of Personalized BiologicsSemantic proximity Read

Beyond antibodies: using biological principles to guide the development of next-generation protein therapeuticsSemantic proximity Read

Therapeutic antibodies: Discovery and development using the ProteOn XPR36 biosensor interaction array system.Semantic proximity Read

The Challenges and Breakthroughs in the Development of Diagnostic Monoclonal AntibodiesSemantic proximity Read